Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESLANASDAQ:GLSINASDAQ:PRQRNASDAQ:RAPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESLAEstrella Immunopharma$0.96+4.3%$0.99$0.63▼$3.23$33.27M0.37125,975 shs4,602 shsGLSIGreenwich LifeSciences$9.05+3.3%$9.58$8.06▼$18.15$117.11M1.6946,178 shs45,034 shsPRQRProQR Therapeutics$2.03+4.1%$1.66$1.07▼$4.62$205.16M0.31644,770 shs255,122 shsRAPTRapt Therapeutics$8.22+10.5%$7.48$5.67▼$30.60$123.03M-0.11161,241 shs87,881 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESLAEstrella Immunopharma+4.35%+6.67%-7.69%-2.04%+2.55%GLSIGreenwich LifeSciences+3.31%+0.22%-7.75%-14.86%-41.61%PRQRProQR Therapeutics+4.10%+7.41%+21.56%+33.55%+23.03%RAPTRapt Therapeutics+10.48%+4.85%-16.46%-29.14%-68.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationESLAEstrella Immunopharma2.1475 of 5 stars3.53.00.00.00.01.70.0GLSIGreenwich LifeSciences1.5354 of 5 stars3.51.00.00.00.03.30.0PRQRProQR Therapeutics1.2776 of 5 stars3.63.00.00.00.00.00.0RAPTRapt Therapeutics3.8139 of 5 stars3.21.00.04.21.81.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESLAEstrella Immunopharma 3.00Buy$16.001,566.67% UpsideGLSIGreenwich LifeSciences 3.00Buy$39.00330.94% UpsidePRQRProQR Therapeutics 3.13Buy$8.00294.09% UpsideRAPTRapt Therapeutics 2.33Hold$24.00191.97% UpsideCurrent Analyst Ratings BreakdownLatest ESLA, PRQR, RAPT, and GLSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025ESLAEstrella ImmunopharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.005/22/2025RAPTRapt TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$16.00 ➝ $8.005/22/2025RAPTRapt TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$48.005/13/2025PRQRProQR TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $9.004/29/2025PRQRProQR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$8.004/29/2025PRQRProQR TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.004/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESLAEstrella ImmunopharmaN/AN/AN/AN/A$0.12 per shareN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.19 per shareN/APRQRProQR Therapeutics$20.46M10.44N/AN/A$0.91 per share2.23RAPTRapt Therapeutics$1.53M88.86N/AN/A$11.51 per share0.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESLAEstrella Immunopharma-$7.31M-$0.26N/A∞N/AN/A-1,132.38%-273.91%N/AGLSIGreenwich LifeSciences-$15.79M-$1.26N/AN/AN/AN/A-450.87%-333.18%8/12/2025 (Estimated)PRQRProQR Therapeutics-$30.04M-$0.35N/AN/AN/A-157.04%-53.49%-22.07%8/4/2025 (Estimated)RAPTRapt Therapeutics-$129.87M-$19.20N/AN/AN/AN/A-81.47%-70.24%8/6/2025 (Estimated)Latest ESLA, PRQR, RAPT, and GLSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025GLSIGreenwich LifeSciences-$0.24-$0.25-$0.01-$0.25N/AN/A5/8/2025Q1 2025PRQRProQR Therapeutics-$0.09-$0.1082-$0.0182-$0.11$4.90 million$4.89 million5/8/2025Q1 2025RAPTRapt Therapeutics-$2.48-$0.64+$1.84-$0.08N/AN/A4/15/2025Q4 2024GLSIGreenwich LifeSciences-$0.21-$0.61-$0.40-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ARAPTRapt TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESLAEstrella ImmunopharmaN/A0.220.22GLSIGreenwich LifeSciencesN/A1.911.91PRQRProQR TherapeuticsN/A4.104.10RAPTRapt TherapeuticsN/A21.1121.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESLAEstrella Immunopharma0.35%GLSIGreenwich LifeSciences4.16%PRQRProQR Therapeutics32.65%RAPTRapt Therapeutics99.09%Insider OwnershipCompanyInsider OwnershipESLAEstrella Immunopharma55.10%GLSIGreenwich LifeSciences51.67%PRQRProQR Therapeutics8.40%RAPTRapt Therapeutics6.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESLAEstrella ImmunopharmaN/A36.17 million16.24 millionNot OptionableGLSIGreenwich LifeSciences313.37 million6.46 millionNot OptionablePRQRProQR Therapeutics180105.21 million96.38 millionOptionableRAPTRapt Therapeutics8016.54 million15.45 millionOptionableESLA, PRQR, RAPT, and GLSI HeadlinesRecent News About These CompaniesRAPT Therapeutics Names Two Industry Veterans to its Board of DirectorsJune 23 at 8:00 AM | globenewswire.comRapt Therapeutics (NASDAQ:RAPT) Downgraded by Wall Street Zen to SellJune 22 at 2:25 AM | americanbankingnews.comRapt Therapeutics (NASDAQ:RAPT) Lowered to Sell Rating by Wall Street ZenJune 21, 2025 | marketbeat.comRapt Therapeutics (NASDAQ:RAPT) Shares Gap Down - Time to Sell?June 18, 2025 | marketbeat.comWall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should KnowJune 18, 2025 | zacks.comRAPT Finalizes Reverse Split Plan; 1-for-8 Ratio Effective June 16, 2025June 15, 2025 | nasdaq.comRAPT Therapeutics, Inc. Announces 1-for-8 Reverse Stock Split Effective June 16, 2025June 15, 2025 | nasdaq.comRAPT Therapeutics (NASDAQ:RAPT) Shares Scheduled to Reverse Split on Tuesday, June 17thJune 13, 2025 | marketbeat.comRAPT Therapeutics, Inc.: RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock SplitJune 13, 2025 | finanznachrichten.deRAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock SplitJune 13, 2025 | globenewswire.comTwo Sigma Investments LP Sells 339,957 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT)June 12, 2025 | marketbeat.comClear Street initiates Rapt Therapeutics stock with buy ratingJune 7, 2025 | uk.investing.comRapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash PositionJune 6, 2025 | msn.comRapt Therapeutics cuts staff for 2nd time in under a year, continuing fallout from FDA holdJune 4, 2025 | fiercebiotech.comRAPT Therapeutics to Participate in Upcoming Investor ConferencesJune 4, 2025 | globenewswire.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from BrokeragesJune 3, 2025 | marketbeat.comShort Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Rises By 39.9%June 2, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for RAPT Q2 Earnings?May 27, 2025 | marketbeat.com12 Health Care Stocks Moving In Friday's Intraday SessionMay 25, 2025 | benzinga.comRapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should KnowMay 16, 2025 | zacks.comRAPT Therapeutics Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesUber Stock Ready to Ride Higher on Waymo PartnershipBy Gabriel Osorio-Mazilli | May 28, 2025View Uber Stock Ready to Ride Higher on Waymo PartnershipTesla: Why Analysts Think It Could Jump Another 47%By Sam Quirke | May 27, 2025View Tesla: Why Analysts Think It Could Jump Another 47%Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?By Nathan Reiff | June 20, 2025View Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?5 Stocks Set to Soar This SummerBy Ryan Hasson | June 2, 2025View 5 Stocks Set to Soar This SummerTesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead?By Gabriel Osorio-Mazilli | June 9, 2025View Tesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead?ESLA, PRQR, RAPT, and GLSI Company DescriptionsEstrella Immunopharma NASDAQ:ESLA$0.96 +0.04 (+4.35%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$0.91 -0.05 (-5.62%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Greenwich LifeSciences NASDAQ:GLSI$9.05 +0.29 (+3.31%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$9.08 +0.03 (+0.33%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.ProQR Therapeutics NASDAQ:PRQR$2.03 +0.08 (+4.10%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$2.02 0.00 (-0.25%) As of 06/24/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.Rapt Therapeutics NASDAQ:RAPT$8.22 +0.78 (+10.48%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$8.24 +0.02 (+0.29%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Insiders Chase Income and Stability in American Tower—Here’s Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
